Concepts (266)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 15 | 2026 | 45 | 2.450 |
Why?
|
| Antiviral Agents | 15 | 2026 | 85 | 1.590 |
Why?
|
| Hepatitis B, Chronic | 5 | 2023 | 20 | 1.300 |
Why?
|
| Liver Cirrhosis | 8 | 2026 | 31 | 1.200 |
Why?
|
| Hepatitis C | 7 | 2023 | 47 | 1.150 |
Why?
|
| Stroke | 2 | 2026 | 309 | 0.940 |
Why?
|
| Humans | 64 | 2026 | 17622 | 0.890 |
Why?
|
| Female | 53 | 2026 | 12715 | 0.880 |
Why?
|
| Liver Cirrhosis, Biliary | 4 | 2026 | 4 | 0.870 |
Why?
|
| Hawaii | 15 | 2026 | 62 | 0.860 |
Why?
|
| Coronary Disease | 1 | 2025 | 145 | 0.840 |
Why?
|
| Sustained Virologic Response | 7 | 2026 | 12 | 0.720 |
Why?
|
| Male | 35 | 2026 | 10014 | 0.710 |
Why?
|
| Middle Aged | 31 | 2026 | 7954 | 0.680 |
Why?
|
| Adult | 30 | 2026 | 7621 | 0.640 |
Why?
|
| Aged | 23 | 2026 | 6223 | 0.630 |
Why?
|
| Risk Factors | 16 | 2026 | 3291 | 0.620 |
Why?
|
| Quality of Life | 4 | 2023 | 505 | 0.590 |
Why?
|
| Retrospective Studies | 13 | 2026 | 2502 | 0.570 |
Why?
|
| Stress, Psychological | 1 | 2020 | 141 | 0.560 |
Why?
|
| United States | 19 | 2026 | 3922 | 0.550 |
Why?
|
| Health Status | 1 | 2020 | 291 | 0.540 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2023 | 22 | 0.530 |
Why?
|
| Lactation | 3 | 2026 | 38 | 0.530 |
Why?
|
| Suicide | 3 | 2024 | 116 | 0.520 |
Why?
|
| Liver Neoplasms | 3 | 2023 | 36 | 0.520 |
Why?
|
| Lung Neoplasms | 3 | 2025 | 278 | 0.470 |
Why?
|
| Hepacivirus | 9 | 2024 | 36 | 0.460 |
Why?
|
| Ursodeoxycholic Acid | 3 | 2026 | 3 | 0.450 |
Why?
|
| Incidence | 9 | 2026 | 1278 | 0.450 |
Why?
|
| Breast Feeding | 3 | 2026 | 119 | 0.450 |
Why?
|
| Mental Disorders | 3 | 2022 | 276 | 0.430 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2026 | 689 | 0.420 |
Why?
|
| Patient Health Questionnaire | 2 | 2024 | 18 | 0.410 |
Why?
|
| Cholagogues and Choleretics | 2 | 2025 | 2 | 0.390 |
Why?
|
| Healthcare Disparities | 3 | 2026 | 208 | 0.370 |
Why?
|
| Cataract Extraction | 1 | 2012 | 2 | 0.370 |
Why?
|
| Cataract | 1 | 2012 | 12 | 0.360 |
Why?
|
| Adolescent | 20 | 2024 | 3625 | 0.350 |
Why?
|
| Rural Population | 1 | 2012 | 58 | 0.350 |
Why?
|
| Electronic Health Records | 3 | 2026 | 719 | 0.350 |
Why?
|
| Prevalence | 5 | 2023 | 830 | 0.340 |
Why?
|
| Vaccination | 2 | 2026 | 726 | 0.330 |
Why?
|
| Coinfection | 2 | 2023 | 23 | 0.330 |
Why?
|
| Hepatitis B | 2 | 2023 | 41 | 0.320 |
Why?
|
| Mental Health | 2 | 2023 | 163 | 0.320 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 2 | 2022 | 12 | 0.310 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 2 | 2007 | 5 | 0.300 |
Why?
|
| Diet | 3 | 2007 | 355 | 0.300 |
Why?
|
| Alkaline Phosphatase | 2 | 2025 | 9 | 0.290 |
Why?
|
| Cohort Studies | 12 | 2024 | 2502 | 0.270 |
Why?
|
| Absorptiometry, Photon | 4 | 2011 | 54 | 0.270 |
Why?
|
| California | 5 | 2026 | 2433 | 0.270 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2026 | 168 | 0.260 |
Why?
|
| Pregnancy | 4 | 2026 | 1565 | 0.250 |
Why?
|
| Self-Injurious Behavior | 2 | 2024 | 44 | 0.250 |
Why?
|
| Milk, Human | 1 | 2026 | 9 | 0.250 |
Why?
|
| Portal Vein | 1 | 2026 | 1 | 0.240 |
Why?
|
| Venous Thrombosis | 1 | 2026 | 23 | 0.240 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2006 | 7 | 0.240 |
Why?
|
| Language | 1 | 2026 | 52 | 0.240 |
Why?
|
| Young Adult | 9 | 2026 | 2538 | 0.240 |
Why?
|
| Feeding Behavior | 2 | 2007 | 163 | 0.240 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2026 | 45 | 0.230 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2025 | 23 | 0.230 |
Why?
|
| Postpartum Period | 1 | 2026 | 93 | 0.230 |
Why?
|
| Heart Failure | 2 | 2025 | 414 | 0.230 |
Why?
|
| Breast Neoplasms | 5 | 2017 | 1005 | 0.230 |
Why?
|
| Mastitis | 1 | 2024 | 2 | 0.220 |
Why?
|
| Hepatitis B virus | 3 | 2023 | 21 | 0.220 |
Why?
|
| Surveys and Questionnaires | 5 | 2026 | 1296 | 0.220 |
Why?
|
| International Classification of Diseases | 1 | 2024 | 85 | 0.210 |
Why?
|
| Clozapine | 1 | 2024 | 6 | 0.210 |
Why?
|
| Obesity | 3 | 2024 | 821 | 0.210 |
Why?
|
| Guideline Adherence | 1 | 2025 | 155 | 0.210 |
Why?
|
| Body Mass Index | 4 | 2022 | 959 | 0.210 |
Why?
|
| Aminoisobutyric Acids | 1 | 2024 | 1 | 0.210 |
Why?
|
| Cyclopropanes | 1 | 2024 | 1 | 0.210 |
Why?
|
| Lactams, Macrocyclic | 1 | 2024 | 1 | 0.210 |
Why?
|
| Benzimidazoles | 1 | 2024 | 5 | 0.210 |
Why?
|
| Myocardial Infarction | 1 | 2026 | 226 | 0.210 |
Why?
|
| Proline | 1 | 2024 | 5 | 0.210 |
Why?
|
| Sulfonamides | 1 | 2024 | 14 | 0.210 |
Why?
|
| Leucine | 1 | 2024 | 4 | 0.210 |
Why?
|
| Adipose Tissue | 5 | 2011 | 67 | 0.200 |
Why?
|
| Antipsychotic Agents | 1 | 2024 | 50 | 0.200 |
Why?
|
| ras Proteins | 2 | 2014 | 20 | 0.200 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2014 | 32 | 0.200 |
Why?
|
| Psychotic Disorders | 1 | 2024 | 52 | 0.200 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2023 | 9 | 0.190 |
Why?
|
| Latent Tuberculosis | 1 | 2023 | 14 | 0.190 |
Why?
|
| African Americans | 3 | 2020 | 429 | 0.190 |
Why?
|
| Treatment Outcome | 6 | 2025 | 1161 | 0.190 |
Why?
|
| Opportunistic Infections | 1 | 2022 | 7 | 0.190 |
Why?
|
| Ribavirin | 2 | 2019 | 6 | 0.190 |
Why?
|
| Time Factors | 6 | 2026 | 1038 | 0.190 |
Why?
|
| Breast | 3 | 2011 | 85 | 0.180 |
Why?
|
| Carbonated Beverages | 3 | 2007 | 15 | 0.180 |
Why?
|
| Risk Assessment | 6 | 2026 | 1093 | 0.180 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 527 | 0.170 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 269 | 0.170 |
Why?
|
| Pregnancy Outcome | 1 | 2022 | 162 | 0.170 |
Why?
|
| Weight Gain | 1 | 2022 | 165 | 0.170 |
Why?
|
| Overweight | 1 | 2022 | 266 | 0.160 |
Why?
|
| Autism Spectrum Disorder | 1 | 2023 | 164 | 0.160 |
Why?
|
| Psychology | 1 | 2020 | 14 | 0.160 |
Why?
|
| Physician's Role | 1 | 2020 | 26 | 0.160 |
Why?
|
| Psychiatry | 1 | 2020 | 22 | 0.160 |
Why?
|
| Unemployment | 1 | 2020 | 12 | 0.160 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 21 | 0.150 |
Why?
|
| Prospective Studies | 5 | 2023 | 1251 | 0.140 |
Why?
|
| Puberty | 2 | 2011 | 58 | 0.140 |
Why?
|
| China | 2 | 2024 | 132 | 0.140 |
Why?
|
| Mental Health Services | 1 | 2020 | 155 | 0.140 |
Why?
|
| Virus Activation | 1 | 2018 | 4 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 46 | 0.140 |
Why?
|
| Social Support | 1 | 2020 | 215 | 0.140 |
Why?
|
| Comorbidity | 1 | 2020 | 552 | 0.140 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 545 | 0.140 |
Why?
|
| Child | 8 | 2023 | 2485 | 0.130 |
Why?
|
| Neoplasms | 1 | 2022 | 457 | 0.130 |
Why?
|
| Liver | 1 | 2017 | 31 | 0.130 |
Why?
|
| Health Policy | 1 | 2018 | 106 | 0.130 |
Why?
|
| Gene Library | 1 | 2017 | 4 | 0.130 |
Why?
|
| Paraffin Embedding | 1 | 2017 | 5 | 0.130 |
Why?
|
| Calcium, Dietary | 3 | 2007 | 28 | 0.130 |
Why?
|
| Colorectal Neoplasms | 2 | 2014 | 642 | 0.130 |
Why?
|
| Suicidal Ideation | 3 | 2024 | 99 | 0.130 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 32 | 0.130 |
Why?
|
| Suicide, Attempted | 1 | 2018 | 93 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2017 | 17 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 380 | 0.130 |
Why?
|
| Menarche | 2 | 2009 | 28 | 0.130 |
Why?
|
| Viral Load | 1 | 2017 | 110 | 0.130 |
Why?
|
| Tuberculosis | 1 | 2017 | 23 | 0.130 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2017 | 53 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2018 | 248 | 0.120 |
Why?
|
| Sex Distribution | 2 | 2017 | 174 | 0.120 |
Why?
|
| Age Distribution | 2 | 2017 | 230 | 0.120 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 1295 | 0.120 |
Why?
|
| Disease Progression | 2 | 2026 | 266 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 1976 | 0.110 |
Why?
|
| Cause of Death | 3 | 2021 | 179 | 0.110 |
Why?
|
| Proportional Hazards Models | 3 | 2026 | 702 | 0.100 |
Why?
|
| Age Factors | 4 | 2019 | 874 | 0.100 |
Why?
|
| ErbB Receptors | 1 | 2012 | 5 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 7 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2015 | 232 | 0.090 |
Why?
|
| Skinfold Thickness | 3 | 2006 | 18 | 0.090 |
Why?
|
| Minority Groups | 2 | 2023 | 104 | 0.080 |
Why?
|
| Biomarkers | 2 | 2025 | 302 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2012 | 137 | 0.080 |
Why?
|
| Prognosis | 3 | 2020 | 609 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2022 | 1107 | 0.080 |
Why?
|
| Iron, Dietary | 2 | 2007 | 8 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 1157 | 0.080 |
Why?
|
| Dietary Fiber | 2 | 2007 | 60 | 0.070 |
Why?
|
| Depression | 2 | 2024 | 507 | 0.070 |
Why?
|
| Asian Americans | 2 | 2020 | 160 | 0.070 |
Why?
|
| Nutritional Requirements | 1 | 2007 | 4 | 0.070 |
Why?
|
| Body Fat Distribution | 1 | 2007 | 4 | 0.070 |
Why?
|
| Dietary Sucrose | 1 | 2007 | 13 | 0.070 |
Why?
|
| Nutrition Policy | 1 | 2007 | 18 | 0.070 |
Why?
|
| Skin | 1 | 2007 | 12 | 0.060 |
Why?
|
| Sunlight | 1 | 2007 | 13 | 0.060 |
Why?
|
| Vitamin D Deficiency | 1 | 2007 | 24 | 0.060 |
Why?
|
| European Continental Ancestry Group | 2 | 2020 | 470 | 0.060 |
Why?
|
| Smoking | 2 | 2022 | 420 | 0.060 |
Why?
|
| Vitamin D | 1 | 2007 | 76 | 0.060 |
Why?
|
| Survival Rate | 2 | 2020 | 252 | 0.060 |
Why?
|
| Asia | 1 | 2006 | 12 | 0.060 |
Why?
|
| Folic Acid | 1 | 2006 | 29 | 0.060 |
Why?
|
| Diet Surveys | 1 | 2006 | 56 | 0.060 |
Why?
|
| Propensity Score | 1 | 2026 | 80 | 0.060 |
Why?
|
| Mitochondria | 1 | 2025 | 7 | 0.060 |
Why?
|
| Milk | 1 | 2004 | 8 | 0.050 |
Why?
|
| Longitudinal Studies | 3 | 2018 | 686 | 0.050 |
Why?
|
| Smoke | 1 | 2024 | 7 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2024 | 1 | 0.050 |
Why?
|
| Pruritus | 1 | 2023 | 2 | 0.050 |
Why?
|
| Quinoxalines | 1 | 2024 | 11 | 0.050 |
Why?
|
| Bone Density | 1 | 2004 | 96 | 0.050 |
Why?
|
| Infant Formula | 1 | 2003 | 10 | 0.050 |
Why?
|
| Logistic Models | 2 | 2019 | 866 | 0.050 |
Why?
|
| Schizophrenia | 1 | 2024 | 76 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 30 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2014 | 21 | 0.050 |
Why?
|
| Genotype | 1 | 2024 | 224 | 0.050 |
Why?
|
| Population Groups | 1 | 2023 | 7 | 0.050 |
Why?
|
| Body Weight | 1 | 2004 | 203 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 319 | 0.050 |
Why?
|
| Genetic Testing | 2 | 2014 | 73 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 152 | 0.050 |
Why?
|
| Mutation | 2 | 2014 | 133 | 0.050 |
Why?
|
| Health Promotion | 1 | 2006 | 293 | 0.050 |
Why?
|
| Child Health | 1 | 2023 | 43 | 0.050 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2022 | 7 | 0.050 |
Why?
|
| Exercise | 2 | 2004 | 538 | 0.050 |
Why?
|
| Regression Analysis | 3 | 2007 | 268 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2020 | 5 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 10 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 19 | 0.040 |
Why?
|
| Health Surveys | 1 | 2020 | 242 | 0.040 |
Why?
|
| Bilirubin | 1 | 2020 | 30 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2020 | 73 | 0.040 |
Why?
|
| Oceanic Ancestry Group | 1 | 2020 | 32 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2019 | 48 | 0.040 |
Why?
|
| Mammography | 2 | 2011 | 173 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 104 | 0.040 |
Why?
|
| Interferons | 1 | 2019 | 4 | 0.040 |
Why?
|
| Washington | 1 | 2020 | 388 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 631 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 42 | 0.040 |
Why?
|
| Hospitalization | 1 | 2024 | 831 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2023 | 1455 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 46 | 0.030 |
Why?
|
| Glycated Hemoglobin A | 1 | 2019 | 179 | 0.030 |
Why?
|
| Hispanic Americans | 1 | 2020 | 370 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2018 | 101 | 0.030 |
Why?
|
| Fibrosis | 1 | 2017 | 6 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 4 | 0.030 |
Why?
|
| Ethnic Groups | 1 | 2020 | 443 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2019 | 319 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 603 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2018 | 142 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2017 | 40 | 0.030 |
Why?
|
| Health Behavior | 1 | 2018 | 348 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 599 | 0.030 |
Why?
|
| Body Composition | 2 | 2007 | 92 | 0.030 |
Why?
|
| Pacific States | 1 | 2015 | 3 | 0.030 |
Why?
|
| Mass Screening | 1 | 2020 | 693 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 177 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2015 | 53 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 35 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 84 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 114 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2019 | 729 | 0.030 |
Why?
|
| Continental Population Groups | 1 | 2015 | 283 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 350 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 99 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 122 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 228 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 63 | 0.020 |
Why?
|
| Family Health | 1 | 2011 | 45 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 214 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 302 | 0.020 |
Why?
|
| Mothers | 1 | 2011 | 105 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 363 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2012 | 256 | 0.020 |
Why?
|
| Polynesia | 1 | 2009 | 2 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2007 | 23 | 0.020 |
Why?
|
| Dietary Proteins | 1 | 2007 | 20 | 0.020 |
Why?
|
| Dietary Carbohydrates | 1 | 2007 | 28 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 46 | 0.020 |
Why?
|
| Diet Records | 1 | 2007 | 37 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2007 | 6 | 0.020 |
Why?
|
| Energy Intake | 1 | 2007 | 97 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2007 | 89 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2007 | 123 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2004 | 55 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2004 | 80 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 37 | 0.010 |
Why?
|
| Anthropometry | 1 | 2003 | 59 | 0.010 |
Why?
|
| Animals | 1 | 2004 | 285 | 0.010 |
Why?
|
| Aging | 1 | 2003 | 159 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2003 | 842 | 0.010 |
Why?
|
Concepts
(266)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(22)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->